Blood test may help some gastric cancer patients avoid unnecessary chemo
NCT ID NCT06157216
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study explores whether a blood test that detects tiny bits of tumor DNA (ctDNA) can help doctors decide if patients with stage II-III gastric cancer need chemotherapy after surgery. About 65 patients will be followed for three years to see if those with no detectable ctDNA can safely receive less intense treatment. The goal is to reduce side effects while still preventing cancer from coming back.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STAGE II-III GASTRIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Jinan Central Hospital
Jinan, Shandong, China
-
Qilu Hospital of Shandong Univertisy
Jinan, Shandong, 250012, China
-
Shandong Provincial Hospital Affiliated to Shandong First Medical University
Jinan, Shandong, 250012, China
-
The Affiliated Hospital of Qingdao University
Qingdao, Shandong, 266000, China
-
Yantai Yuhuangding Hospital
Yantai, Shandong, 264000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.